Kyle Jenne Biography and Net Worth

Executive Vice President, Chief Global Product Strategy Officer of Ionis Pharmaceuticals

Mr. Jenne is Ionis’ executive vice president, chief global product strategy officer. He has more than 25 years of biopharmaceutical experience launching and commercializing innovative medicines in the U.S. and globally. He has broad relevant experience in rare, specialty and common diseases across therapeutic areas including cardiovascular, neurology and allergy.

Mr. Jenne leads all aspects of commercialization including marketing, sales, commercial operations, market access and patient services. He also oversees Ionis’ portfolio planning, market insights and medical affairs functions.

Before rejoining Ionis in 2024, Mr. Jenne previously spent five years in senior commercial leadership roles at Ionis and Akcea, which was fully acquired by Ionis in 2020. During his time at Ionis and Akcea, Mr. Jenne built commercial capabilities in many of Ionis’ key disease areas including transthyretin-mediated amyloidosis and familial chylomicronemia syndrome. Earlier in his career, Mr. Jenne held commercial roles for companies including Schering Plough, King Pharmaceuticals, Acorda Therapeutics and Praecis Pharmaceuticals. Mr. Jenne holds a BS in Marketing from Arizona State University.

What is Kyle Jenne's net worth?: The estimated net worth of Kyle Jenne is at least $1.39 million as of January 16th, 2026. Mr. Jenne owns 16,389 shares of Ionis Pharmaceuticals stock worth more than $1,386,346 as of February 4th. This net worth evaluation does not reflect any other investments that Mr. Jenne may own. Learn More about Kyle Jenne's net worth.
How do I contact Kyle Jenne?: The corporate mailing address for Mr. Jenne and other Ionis Pharmaceuticals executives is 2855 GAZELLE COURT, CARLSBAD CA, 92010. Ionis Pharmaceuticals can also be reached via phone at (760) 931-9200 and via email at [email protected]. Learn More on Kyle Jenne's contact information.
Has Kyle Jenne been buying or selling shares of Ionis Pharmaceuticals?: Over the course of the past ninety days, Kyle Jenne has sold $138,475.08 in Ionis Pharmaceuticals stock. Most recently, Kyle Jenne sold 1,823 shares of the business's stock in a transaction on Friday, January 16th. The shares were sold at an average price of $75.96, for a transaction totalling $138,475.08. Following the completion of the sale, the executive vice president now directly owns 16,389 shares of the company's stock, valued at $1,244,908.44. Learn More on Kyle Jenne's trading history.
Who are Ionis Pharmaceuticals' active insiders?: Ionis Pharmaceuticals' insider roster includes Joseph Baroldi (EVP & Chief Business Officer), C. Bennett (EVP), Spencer Berthelsen (Director), Brian Birchler (EVP), Onaiza Cadoret-Manier (EVP), Breaux Castleman (Director), Stanley Crooke (Chairman), Shannon Devers (Executive Vice President, Chief Human Resources Officer), Allene Diaz (Director), Richard Geary (EVP), Michael Hayden (Director), Elizabeth Hougen (CFO), Kyle Jenne (Executive Vice President, Chief Global Product Strategy Officer), Joseph Klein, III (Director), Holly Kordasiewicz (Executive Vice President, Chief Development Officer), Brett Monia (CEO), Frederick Muto (Director), Patrick O'Neil (EVP), B. Parshall, Esq. (Director), Eugene Schneider (EVP), Eric Swayze (EVP), and Joseph Wender (Director). Learn More on Ionis Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Ionis Pharmaceuticals?: During the last year, Ionis Pharmaceuticals insiders bought shares 1 times. They purchased a total of 15,000 shares worth more than $477,900.00. During the last year, insiders at the sold shares 76 times. They sold a total of 1,346,160 shares worth more than $89,921,385.44. The most recent insider tranaction occured on January, 30th when EVP Eric Swayze sold 6,179 shares worth more than $512,424.47. Insiders at Ionis Pharmaceuticals own 2.7% of the company. Learn More about insider trades at Ionis Pharmaceuticals.
Information on this page was last updated on 1/30/2026.

Kyle Jenne Insider Trading History at Ionis Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/16/2026	Sell	1,823	$75.96	$138,475.08	16,389

Kyle Jenne Buying and Selling Activity at Ionis Pharmaceuticals

Ionis Pharmaceuticals Company Overview

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Today's Range

Now: $84.59

$83.00

$85.45

50 Day Range

MA: $80.42

$76.33

$84.59

2 Week Range

Now: $84.59

$23.95

$86.15

Volume

1,453,463 shs

Average Volume

2,349,598 shs

Market Capitalization

$13.70 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.29